Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.58 |
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.50 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22117671 | 0.96 | GPR119 (0.56) | GPR119NAMPTDDB1CRBNALDH1A1 | |
| SCHEMBL19160548 | 0.90 | NAMPT (0.55) | GPR119NAMPTDDB1CRBNALDH1A1 | |
| SCHEMBL25927852 | 0.88 | GPR119 (0.59) | GPR119NAMPTDDB1CRBN | |
| SCHEMBL22137691 | 0.87 | GPR119 (0.57) | GPR119NAMPTDDB1CRBNALDH1A1 | |
| SCHEMBL23250039 | 0.86 | GPR119 (0.54) | GPR119NAMPTDDB1CRBN | |
| SCHEMBL22117623 | 0.86 | GPR119 (0.53) | GPR119NAMPTDDB1CRBNALDH1A1 | |
| SCHEMBL23411133 | 0.83 | LIPE (0.57) | GPR119NAMPTDDB1CRBNALDH1A1 | |
| SCHEMBL5577703 | 0.83 | NAMPT (0.57) | GPR119NAMPTDDB1CRBN | |
| SCHEMBL4177220 | 0.82 | GPR119 (0.60) | GPR119NAMPTDDB1CRBNALDH1A1 | |
| SCHEMBL7871974 | 0.82 | ALDH1A1 (0.67) | GPR119NAMPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230035133-A1 | [1,2,4]Triazolo[4,3-B]Pyridazines For Use in the Treatment of Proliferative Diseases | ASTRAZENECA AB (SE) | 2023-02-02 | — | — | US | disclosed |
| US-20230035133-A1 | [1,2,4]Triazolo[4,3-B]Pyridazines For Use in the Treatment of Proliferative Diseases | ASTRAZENECA AB (SE) | 2023-02-02 | — | — | US | disclosed |
| US-11407755-B2 | [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases | ASTRAZENECA AB (SE) | 2022-08-09 | — | — | US | disclosed |
| US-20210107905-A1 | 1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2021-04-15 | — | — | US | disclosed |
| US-20210107905-A1 | 1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2021-04-15 | — | — | US | disclosed |
| US-10766905-B2 | [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases | ASTRAZENECA AB (SE) | 2020-09-08 | — | — | US | disclosed |
| US-10766905-B2 | [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases | ASTRAZENECA AB (SE) | 2020-09-08 | — | — | US | disclosed |
| US-20200055861-A1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA UK LIMITED (GB) | 2020-02-20 | — | — | US | disclosed |
| US-20200055861-A1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA UK LIMITED (GB) | 2020-02-20 | — | — | US | disclosed |
| US-10407432-B2 | [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases | ASTRAZENECA AB (SE) | 2019-09-10 | — | — | US | disclosed |
| US-10407432-B2 | [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases | ASTRAZENECA AB (SE) | 2019-09-10 | — | — | US | disclosed |
| US-9944650-B2 | [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases | ASTRAZENECA AB (SE) | 2018-04-17 | — | — | US | disclosed |
| US-9944650-B2 | [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases | ASTRAZENECA AB (SE) | 2018-04-17 | — | — | US | disclosed |
| US-9944650-B2 | [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases | ASTRAZENECA AB (SE) | 2018-04-17 | — | — | US | disclosed |
| EP-3174881-B1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2018-03-28 | — | — | EP | disclosed |
| EP-3174881-B1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2018-03-28 | — | — | EP | disclosed |
| US-20170210747-A1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2017-07-27 | — | — | US | disclosed |
| US-20170210747-A1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2017-07-27 | — | — | US | disclosed |
| US-20170210747-A1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2017-07-27 | — | — | US | disclosed |
| WO-2016016618-A1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407432-B2 | [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases | MKI67, CCNB1, CCNB2 | GPR119 2809/4885NAMPT 1294/4885DDB1 888/4885 |
| US-20200055861-A1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | MKI67, CCNB1, CCNB2 | GPR119 2809/4885NAMPT 1294/4885DDB1 888/4885 |
| US-20210107905-A1 | 1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | MKI67, CCNB1, BCL2 | GPR119 2783/4885NAMPT 1338/4885DDB1 653/4885 |
| US-20170210747-A1 | [1,2,4]TRIAZOLO[4,3-B]PYRIDAZINES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES | MKI67, CCNI, CCNB1 | GPR119 2468/4885NAMPT 1302/4885DDB1 933/4885 |
| US-11407755-B2 | [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases | MKI67, CCNB1, CCNB2 | GPR119 2809/4885NAMPT 1294/4885DDB1 888/4885 |
| US-20230035133-A1 | [1,2,4]Triazolo[4,3-B]Pyridazines For Use in the Treatment of Proliferative Diseases | MKI67, CCNB1, CCNB2 | GPR119 2809/4885NAMPT 1294/4885DDB1 888/4885 |
| US-10766905-B2 | [1,2,4]triazolo[4,3-B]pyridazines for use in the treatment of proliferative diseases | MKI67, CCNB1, CCNB2 | GPR119 2809/4885NAMPT 1294/4885DDB1 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.